Pharmaceutical_foot | Wall Street Endeavor

top of page

WSE_logo_artwork-rgb_outline_dark green.png

Worthy Endeavor: Vivos Closes $12 Million Stock Deal as Funding Pressure Persists

Worthy Endeavor: Vivos Closes $12 Million Stock Deal as Funding Pressure Persists

Worthy Endeavor: Vivos Closes $12 Million Stock Deal as Funding Pressure Persists

2 days ago1 min read

Worthy Endeavor: SciSparc’s AI Pivot Sparks Trading Frenzy

Worthy Endeavor: SciSparc’s AI Pivot Sparks Trading Frenzy

Worthy Endeavor: SciSparc’s AI Pivot Sparks Trading Frenzy

Worthy Endeavors

6 days ago1 min read

WSE’s Pick of the Week: Quantum-Si Is One Step Away From a Major Breakthrough

WSE’s Pick of the Week: Quantum-Si Is One Step Away From a Major Breakthrough

WSE’s Pick of the Week: Quantum-Si Is One Step Away From a Major Breakthrough

Worthy Endeavors

6 days ago2 min read

Liquidia Pays $380.7 Million to Clear YUTREPIA’s Legal Path

Liquidia Pays $380.7 Million to Clear YUTREPIA’s Legal Path

Liquidia Pays $380.7 Million to Clear YUTREPIA’s Legal Path

Oct 151 min read

UnitedHealth’s Earnings Beat Strengthens Its Turnaround

UnitedHealth’s Earnings Beat Strengthens Its Turnaround

UnitedHealth’s Earnings Beat Strengthens Its Turnaround

Oct 131 min read

Shionogi Bets $2 Billion on a US Rare-Disease Drugmaker

Shionogi Bets $2 Billion on a US Rare-Disease Drugmaker

Shionogi Bets $2 Billion on a US Rare-Disease Drugmaker

Pharma Investments

Oct 61 min read

Novartis Makes $7.8 Billion Bet on the Next Wave of RNA Drugs

Novartis Makes $7.8 Billion Bet on the Next Wave of RNA Drugs

Novartis Makes $7.8 Billion Bet on the Next Wave of RNA Drugs

Oct 51 min read

Eli Lilly’s Next Obesity Drug Raises the Bar Again

Eli Lilly’s Next Obesity Drug Raises the Bar Again

Eli Lilly’s Next Obesity Drug Raises the Bar Again

Oct 11 min read

Novo Nordisk’s $23 Billion Growth Plan Fails to Reassure Investors

Novo Nordisk’s $23 Billion Growth Plan Fails to Reassure Investors

Novo Nordisk’s $23 Billion Growth Plan Fails to Reassure Investors

Pharma Investments

Sep 212 min read

GSK’s Cancer Comeback Just Passed Another Important Test

GSK’s Cancer Comeback Just Passed Another Important Test

GSK’s Cancer Comeback Just Passed Another Important Test

Sep 153 min read

Eli Lilly's Next Obesity Drug Could Raise the Bar Again

Eli Lilly's Next Obesity Drug Could Raise the Bar Again

Eli Lilly's Next Obesity Drug Could Raise the Bar Again

Sep 142 min read

Tempus Isn't Just Buying a Cancer Testing Company, It's Buying an AI Advantage

Tempus Isn't Just Buying a Cancer Testing Company, It's Buying an AI Advantage

Tempus Isn't Just Buying a Cancer Testing Company, It's Buying an AI Advantage

Sep 142 min read

The AI Drug Revolution Is Finally Facing Its Biggest Test

The AI Drug Revolution Is Finally Facing Its Biggest Test

The AI Drug Revolution Is Finally Facing Its Biggest Test

Sep 142 min read

Cancer treatment could identify patients most likely to respond to cancer drugs

Cancer treatment could identify patients most likely to respond to cancer drugs

Cancer treatment could identify patients most likely to respond to cancer drugs

Aug 102 min read

bottom of page